Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Discov. 2021 May;11(5):1008-1010. doi: 10.1158/2159-8290.CD-21-0257.
Although combination anti-PD-1 and anti-CTLA4 mAbs have revolutionized outcomes for many cancers, their utility has been limited due to significant immune-related toxicities and the emergence of resistance. In this issue of , Dovedi and colleagues describe the development and preclinical testing of MEDI5752, a bispecific anti-PD-1/CTLA4 antibody designed to optimize therapeutic response by maximizing CTLA4 blockade on antigen-experienced T cells, thereby increasing efficacy and potentially minimizing toxicity..
虽然抗 PD-1 和抗 CTLA4 mAbs 的联合应用已经彻底改变了许多癌症的治疗结果，但由于其严重的免疫相关毒性和耐药性的出现，其应用受到限制。在本期 杂志中，Dovedi 及其同事描述了 MEDI5752 的开发和临床前测试，这是一种双特异性抗 PD-1/CTLA4 抗体，旨在通过最大化 CTLA4 在抗原经验性 T 细胞上的阻断来优化治疗反应，从而提高疗效并可能最大限度地降低毒性。
